IP Library Granted Patent US 9,682,046
Granted Patent B2
US 9,682,046 · App. 14/349,512 · Granted Jun 20, 2017

Adsorbents for oral administration

Inventors: Yasumi Nishiwaki (Hino, JP); Takashi Murakami (Hino, JP); Nobuaki Eto (Hino, JP); Keiichiro Imaizumi (Hino, JP); Akihito Ohtaki (Sunto-gun, JP); Kenji Shimazaki (Sunto-gun, JP)
Assignee: Teijin Pharma Limited
A61K9/70A61K31/01A61K33/44B01J20/20B01J20/28004B01J20/2808B01J20/28023B01J20/28066B01J20/28069C01B31/10D01F9/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,682,046
App. No.
14/349,512
Granted
Jun 20, 2017
Kind
B2
Abstract

The present invention aims to provide an adsorbent for oral administration comprising ACF that has high adsorption or removal performance by adsorbing or removing toxic substances in the living body greatly and rapidly. The present invention is an adsorbent for oral administration comprising activated carbon fibers for treating or preventing kidney diseases or dialysis complications.

Claims (7)

1. A method for adsorbing a uremic toxin comprising oral administration of activated carbon fiber to a subject in need thereof;

wherein when the activated carbon fiber is a rayon-based activated carbon fiber, the diameter of the rayon-based activated carbon fiber is at least 9 μm.

2. The method according to claim 1 , wherein the activated carbon fibers have a micropore volume of 0.1 to 2.0 mL/g.

3. The method according to claim 1 , wherein the activated carbon fibers have a fiber length of 15 μm or more and a micropore volume of 0.5 to 1.0 mL/g.

4. The method according to claim 1 whereby kidney diseases or dialysis complications are treated or prevented.

5. The method according to claim 1 , wherein the adsorbent is administered at a daily dose of 1 to 3000 mg.

6. A method for adsorbing a uremic toxin comprising oral administration of activated carbon fiber to a subject in need thereof; wherein the activated carbon fiber has a cross-sectional diameter of the fiber of 5 to 50 μm, a fiber length of 15 μm or more, a specific surface area as determined by BET method of 1400 to 2700 m 2 /g, a total pore volume of 0.8 to 1.8 mL/g, and a micropore volume of 0.5 to 1.0 mL/g; wherein when the activated fiber is a rayon-based activated carbon fiber, the diameter of the rayon-based activated carbon fiber is at least 9 μm.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 26, 2018
From: TEIJIN PHARMA LIMITED
To: TEIJIN LIMITED
Reel/Frame 047322/0604 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 8, 2014
From: NISHIWAKI, YASUMI; MURAKAMI, TAKASHI; ETO, NOBUAKI; IMAIZUMI, KEIICHIRO; OHTAKI, AKIHITO; SHIMAZAKI, KENJI
To: TEIJIN PHARMA LIMITED
Reel/Frame 032847/0124 →
Priority Claims (2)
JP 2011-222949 · Oct 7, 2011 · national
JP 2012-181466 · Aug 20, 2012 · national
Continuity (1)
Related Publication 20140242147A1 · Aug 28, 2014